Join our daily newsletter At The Bell to receive exclusive market insights
Recce Pharmaceuticals Ltd (ASX:RCE) has ticked off completion of all patents for two of its key anti-infectives, with the Australian Patent Office granting ‘Patent Family 3’ status to RECCE 327 (R327) and RECCE 529 (R529).
The latest patent – which expires in 2037 – covers the process for manufacture and a copolymer also made by the same process, the use of both anti-infectives to treat infections, and four different methods of administration (oral, injection, inhalation, and transdermal dose).
With this being the final patent confirmed in Australia, Recce now achieved total patent protection for the anti-infectives across global pharmaceutical markets.
Recce chief executive officer James Graham said receiving complete patent status underscored the significance of these treatments in the fight against life-threatening infections.
“We are thrilled by the Australian Patent Office’s formal recognition of the ground-breaking potential of Recce’s new class of anti-infectives,” he said.
“The granting of Patent Family 3 solidifies our global intellectual property portfolio, providing protection for R327 and R529 across all major pharmaceutical markets until 2037.
“This milestone underscores our commitment to addressing critical viral threats with innovative therapies and ensures we are well-positioned to deliver meaningful solutions for patients worldwide.”
Recce has been trading at 47 cents.
Join the discussion: See what HotCopper users are saying about Recce and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
